These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21304035)

  • 1. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.
    Mease PJ; Zimetbaum PJ; Duh MS; Vekeman F; Guérin A; Boerstoel-Streefland M; Jiang W; Lefebvre P
    Ann Pharmacother; 2011 Feb; 45(2):179-88. PubMed ID: 21304035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark.
    Ishtiak-Ahmed K; Musliner KL; Christensen KS; Mortensen EL; Nierenberg AA; Gasse C
    Am J Psychiatry; 2024 Jan; 181(1):47-56. PubMed ID: 37849303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
    Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
    Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease: A Real-Life Investigation From Italy.
    Biffi A; Rea F; Scotti L; Lucenteforte E; Vannacci A; Lombardi N; Chinellato A; Onder G; Vitale C; Cascini S; Ingrasciotta Y; Roberto G; Mugelli A; Corrao G;
    J Clin Psychopharmacol; 2020; 40(2):112-121. PubMed ID: 32134848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible interaction between milnacipran and warfarin potassium.
    Sawamura J; Kozaki K; Mochizuki S; Ishigooka J
    J Clin Pharmacol; 2012 May; 52(5):780-1. PubMed ID: 22539653
    [No Abstract]   [Full Text] [Related]  

  • 8. Distinct effects of the serotonin-noradrenaline reuptake inhibitors milnacipran and venlafaxine on rat pineal monoamines.
    Muneoka K; Kuwagata M; Ogawa T; Shioda S
    Neuroreport; 2015 Jun; 26(9):510-4. PubMed ID: 26016648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.
    Perry NK
    Postgrad Med J; 2000 Apr; 76(894):254-6. PubMed ID: 10727586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 12. Milnacipran for fibromyalgia.
    Dempsey J
    Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
    Leo RJ; Brooks VL
    Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of milnacipran: an overview.
    Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with duloxetine in adults and the incidence of cardiovascular events.
    Xue F; Strombom I; Turnbull B; Zhu S; Seeger J
    J Clin Psychopharmacol; 2012 Feb; 32(1):23-30. PubMed ID: 22198454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
    Stahl SM; Grady MM; Moret C; Briley M
    CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.
    Montgomery SA
    CNS Spectr; 2008 Jul; 13(7 Suppl 11):27-33. PubMed ID: 18622372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
    Saraceni MM; Venci JV; Gandhi MA
    J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adverse effects of antidepressants and antimanics].
    Tanaka T; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):362-5. PubMed ID: 12877003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.